Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial
Kendrick J, Andrews E, You Z, Moreau K, Nowak KL, Farmer-Bailey H, Seals DR, Chonchol M
Clinical journal of the American Society of Nephrology : CJASN · 36 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- American Society of Nephrology
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- National Center for Research Resources
- Universidad u hospital
- Colorado Clinical and Translational Sciences Institute
- Gobierno
- NIDDK NIH HHS
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK048520); National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK087859); National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK099199); National Center for Research Resources (#UL1 RR025780)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2017-08-07 · Clin J Am Soc Nephrol · vol. 12 · número 9 · págs. 1438–1446
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 44 citas · más que el 96% de estudios similares · 4.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 48 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Nitric Oxide and Endothelin Effects
- Palabras clave
- Calcitriol, Cholecalciferol, Medicine, Vitamin D and neurology, Internal medicine, vitamin D deficiency, Endocrinology, Gastroenterology, Urology
- MeSH
- kidney, brachial artery, humans, cholecalciferol, calcitriol, vitamin d, inflammation mediators, glomerular filtration rate, treatment outcome, prospective studies, double-blind method, recovery of function, vasodilation, time factors, dietary supplements, aged, middle aged, colorado, female, male, renal insufficiency, chronic, biomarkers
8 autores
- Jessica Kendrick🇺🇸 · autor de correspondenciaDenver Health Medical Center; University of Colorado Denver
- Emily S. Andrews · autor de correspondencia
- Zhiying You · autor de correspondencia
- Kerrie L. Moreau🇺🇸University of Colorado Denver
- Kristen L. Nowak · autor de correspondencia
- Heather Farmer‐Bailey · autor de correspondencia
- Douglas R. Seals🇺🇸University of Colorado Boulder
- Michel Chonchol · autor de correspondencia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and objectives
High circulating vitamin D levels are associated with lower cardiovascular mortality in CKD, possibly by modifying endothelial function. We examined the effect of calcitriol versus cholecalciferol supplementation on vascular endothelial function in patients with CKD.
Design, setting, participants, & measurements
We performed a prospective, double-blind, randomized trial of 128 adult patients with eGFR=15-44 ml/min per 1.73 m2and serum 25-hydroxyvitamin D level μg) daily for 6 months. The primary end point was change in brachial artery flow-mediated dilation. Secondary end points included changes in circulating markers of mineral metabolism and circulating and cellular markers of inflammation.
Results
One hundred and fifteen patients completed the study. The mean (SD) age and eGFR of participants were 58±12 years old and 33.0±10.2 ml/min per 1.73 m2, respectively. There were no significant differences between groups at baseline. After 6 months, neither calcitriol nor cholecalciferol treatment resulted in a significant improvement in flow-mediated dilation (mean±SD percentage flow-mediated dilation; calcitriol: baseline 4.8±3.1%, end of study 5.1±3.6%; cholecalciferol: baseline 5.2±5.2%, end of study 4.7±3.6%); 25-hydroxyvitamin D levels increased significantly in the cholecalciferol group compared with the calcitriol group (cholecalciferol: 11.0±9.5 ng/ml; calcitriol: -0.8±4.8 ng/ml; PP=0.004).
Conclusions
Six months of therapy with calcitriol or cholecalciferol did not improve vascular endothelial function or improve inflammation in patients with CKD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.